Alignment Healthcare Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Plans
During the fiscal quarter ended December 31, 2024, our executive officers and directors adopted the following trading arrangements that are intended to satisfy the affirmative defense of Rule 10b5-1(c):
| Name and Title | Date of Adoption | Date of Termination | Duration of Trading Arrangement | Number of Securities to be Sold(1) |
|---|---|---|---|---|
| Dawn Maroney, President | 11/25/2024 | N/A | 4/14/2025 - 8/22/2025 | 350,000 |
| Thomas Freeman, Chief Financial Officer(2) | 11/25/2024 | N/A | 2/28/2025 - 11/28/2025 | 352,793 |
| Thomas Freeman, Chief Financial Officer(2) | N/A | 11/20/2024 | 3/14/2024 - 6/13/2025 | 518,000 |
| Christopher Joyce, Chief Legal & Administrative Officer | 11/27/2024 | N/A | 2/26/2025 - 11/14/2025 | 50,678 |
(1) Securities reported in this column include securities subject to limit orders and such orders may not fill if limit order conditions are not met. The actual number of shares sold under the plan will depend on the vesting of certain performance-based equity awards and the number of shares withheld or sold satisfy our income tax withholding obligations and may vary from the number provided herein. Number of performance share units included in plans assumes earned at target.
(2) Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.